AstraZeneca anticipates a challenging financial quarter, expecting earnings per share to fall to $0.84 and revenue to decrease slightly to $11.34 billion. Despite these expected declines, the company has seen a stock increase of 5.25% over the past month and has raised its annual dividend by 35.9% to $1.45 per share, offering a yield of 2.79%. Additionally, AstraZeneca is actively collaborating with Ionis Pharmaceuticals on eplontersen for amyloidosis, committing resources to advance this promising drug.
“Astrazeneca (AZN) · closed at · $68.64 · +0.06% move from the prior day”
“Astrazeneca (AZN) · had gained · 5.25% · in the past month”
“Astrazeneca · expected to report EPS of · $0.84 · down 11.58% from the prior-year quarter”
“Astrazeneca · expected revenue · $11.34 billion · down 0.44% from the prior-year quarter”
“Astrazeneca · currently sporting a Zacks Rank of · #3 · (Hold)”
“AstraZeneca (AZN) · pays investors in dividends annually · $1.45 per share · true”
“AZN's management · has guided for earnings growth · high single-digit to low double-digit · true”
“Astrazeneca · is headquartered in · Cambridge”
“Astrazeneca · is in · the Medical sector”
“Astrazeneca · has seen a price change of · 2.06% since the start of the year”
“Astrazeneca · is paying out a dividend of · $0.96 per share”
“Astrazeneca · has a dividend yield of · 2.79%”
